New research shows that the asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation.
Benralizumab not effective reducing exacerbations in moderate to very severe COPD
by | May 20, 2019 | Asthma in the News | 0 comments